Nextcea
Nextcea Inc. specializes in providing comprehensive drug development services aimed at enhancing efficacy and minimizing toxicity across all stages of drug development. They focus on neurodegenerative diseases and cancer, utilizing advanced LC-MS/MS platforms and collaborating with leading research institutions. Their mission is to improve drug safety and efficacy through innovative biomarker analysis and personalized therapeutics.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Validated LC‑MS/MS assay for di‑22:6‑BMP
A validated LC‑MS/MS assay for quantitative measurement of di‑22:6‑BMP in urine and plasma for DIPL and LRRK2 pharmacodynamic assessments.
Multiplexed kidney safety biomarker assay (UPLC‑MS/MS)
A validated multiplexed assay for simultaneous quantitation of urinary kidney injury proteins to support nephrotoxicity assessment in preclinical and clinical studies.
Selective GCase enzyme activity assay
An assay using a selective substrate to measure active GCase enzyme activity with high specificity relative to generic fluorescent substrates.
Validated LC‑MS/MS assay for di‑22:6‑BMP
A validated LC‑MS/MS assay for quantitative measurement of di‑22:6‑BMP in urine and plasma for DIPL and LRRK2 pharmacodynamic assessments.
Multiplexed kidney safety biomarker assay (UPLC‑MS/MS)
A validated multiplexed assay for simultaneous quantitation of urinary kidney injury proteins to support nephrotoxicity assessment in preclinical and clinical studies.
Selective GCase enzyme activity assay
An assay using a selective substrate to measure active GCase enzyme activity with high specificity relative to generic fluorescent substrates.
Services
Laboratory measurement and reporting of quantitative biomarker data to support efficacy and safety assessments in nonclinical and clinical studies.
Validated LC‑MS/MS measurement of di‑22:6‑BMP in urine and plasma to detect drug‑induced phospholipidosis and lysosomal dysfunction, and to support LRRK2 inhibitor pharmacodynamic assessments.
Multiplexed UPLC‑MS/MS panel to quantify urinary kidney injury protein biomarkers and calculation of a composite PFC Index (geometric mean/PCA) to summarize nephrotoxicity risk.
Measurement of percent protein mutation in patient cancer cells and percent drug occupancy on BTK to assess target engagement, inform dosing, and support personalized therapeutic decisions.
Quantitation of GBA1 protein in CSF and plasma, selective GCase enzyme activity assays, and separation/measurement of GlcCer/GlcSph and GalCer/GalSph stereoisomers with ultra‑sensitivity for Parkinson’s and Gaucher disease studies.
Study sample handling, traceability, secure archival, and QA oversight provided by RQAP‑GLP/GCP personnel to ensure data integrity for regulated studies.
Laboratory measurement and reporting of quantitative biomarker data to support efficacy and safety assessments in nonclinical and clinical studies.
Validated LC‑MS/MS measurement of di‑22:6‑BMP in urine and plasma to detect drug‑induced phospholipidosis and lysosomal dysfunction, and to support LRRK2 inhibitor pharmacodynamic assessments.
Multiplexed UPLC‑MS/MS panel to quantify urinary kidney injury protein biomarkers and calculation of a composite PFC Index (geometric mean/PCA) to summarize nephrotoxicity risk.
Measurement of percent protein mutation in patient cancer cells and percent drug occupancy on BTK to assess target engagement, inform dosing, and support personalized therapeutic decisions.
Quantitation of GBA1 protein in CSF and plasma, selective GCase enzyme activity assays, and separation/measurement of GlcCer/GlcSph and GalCer/GalSph stereoisomers with ultra‑sensitivity for Parkinson’s and Gaucher disease studies.
Study sample handling, traceability, secure archival, and QA oversight provided by RQAP‑GLP/GCP personnel to ensure data integrity for regulated studies.
Expertise Areas
- Bioanalytical method development and validation
- Biomarker discovery and qualification for neurodegenerative diseases
- PK/PD and TK/TD integration with biomarker readouts
- Clinical trial biomarker assays and patient stratification
Key Technologies
- UPLC‑MS/MS / LC‑MS/MS
- Multiplexed biomarker assays
- LIMS and 21 CFR Part 11‑compliant electronic records
- Ultra‑sensitive lipidomics (pg/mL level)